Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination.
BACKGROUND
Melasma has a negative impact on quality of life since it typically occurs on the face.


OBJECTIVE
To evaluate the erythema and pigmentation of melasma lesions and the surrounding areas in patients receiving triple combination (TC: hydroquinone, tretinoin, and fluocinolone acetonide) regimens.


METHODS
Patients first received an 8-week daily TC treatment and were then randomized to twice weekly or tapering regimen with TC. Melanin and erythema levels of lesions and surrounding areas were objectively measured using a narrowband reflectance spectrophotometer.


RESULTS
Progressive reduction in the mean melanin levels was observed in the treatment phase. Following both maintenance regimens, there was no difference between melanin levels in the melasma lesions. Adverse effects were rare in both phases of the study and there was borderline reduction in erythema with regimen II.


CONCLUSIONS
Both maintenance regimens were effective in maintaining results obtained during the initial treatment phase, and were safe and well-tolerated. Erythema was less intense with the tapering regimen.
Doris
D
Hexsel
Mariana
M
Soirefmann
Juliana Dumêt
JD
Fernandes
Carolina
C
Siega
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000975:Antioxidants / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004890:Erythema / Q000473:pathology*; D005446:Fluocinolone Acetonide / Q000008:administration & dosage; D006801:Humans; D006873:Hydroquinones / Q000008:administration & dosage; D007641:Keratolytic Agents / Q000008:administration & dosage; D008134:Long-Term Care; D060046:Maintenance Chemotherapy / Q000009:adverse effects; D008543:Melanins / Q000378:metabolism; D008548:Melanosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D011446:Prospective Studies; D016037:Single-Blind Method; D012867:Skin / Q000473:pathology; D012880:Skin Pigmentation; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D006873:Hydroquinones; D007641:Keratolytic Agents; D008543:Melanins; D005446:Fluocinolone Acetonide; D014212:Tretinoin; C031927:hydroquinone